Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Total Non-current Assets
All assets not expected to be converted to cash within one year.
Entera Bio Ltd.NASDAQ: ENTX
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 66.5% from a year ago
Total non-current assets stood at $636K at the end of Q1 FY2026, up 66.5% from a year earlier and up 374.6% from the prior quarter. Over 3 fiscal years it compounded at -21.6% a year.
Context
- Total non-current assets amounted to 4.8% of total assets at the end of Q1 FY2026, up 3.1 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +66.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 134K USD
- Year-over-year change
- -67.9%
- 4-year CAGR
- -32.8%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 134K | -67.9% |
| FY2024 | 2024-12-31 | 418K | -17.7% |
| FY2023 | 2023-12-31 | 508K | +82.7% |
| FY2022 | 2022-12-31 | 278K | -57.8% |
| FY2021 | 2021-12-31 | 658K | — |
Total Non-current Assets vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 total non-current assets of $636K is the 7th highest of the 10 companies compared; the peer median is $10.34M.
- Its year-over-year change of +66.5% is the 2nd highest of 10, against a peer median of -22.2%.
- Total non-current assets amounts to 4.8% of total assets for ENTX, versus a peer median of 20.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $91.17M | -48.5% | -22.5% | 48.9% | |
| Mar 2026 | $90.54M | -1.6% | +21.3% | 33.3% | |
| Mar 2026 | $85.78M | -12.6% | -16.8% | 72.9% | |
| Mar 2026 | $22.72M | +7152.7% | +269.0% | 76.5% | |
| Mar 2026 | $10.34M | -32.8% | -26.6% | 20.8% | |
| Mar 2026 | $1.41M | -53.0% | -53.0% | 2.4% | |
| Mar 2026 | $636K | +66.5% | -21.6% | 4.8% | |
| Mar 2026 | $535K | -98.9% | -67.1% | 0.4% | |
IRDOpus Genetics, Inc. | Mar 2026 | $186K | -22.2% | +221.3% | 0.3% |
| Apr 2026 | $173K | -18.0% | -3.1% | 1.2% | |
| Peer median (excluding ENTX) | $10.34M | -22.2% | -16.8% | 20.8% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.